Renin increases mesangial cell transforming growth factor-β1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms

Kidney International

Volumn 69, Issue 1, 2006, Pages 105-113

  Huang, Y ^a   Wongamorntham, S ^a   Kasting, J ^a   McQuillan, D ^b   Owens, R T ^b   Yu, L ^a   Noble, N A ^a   Border, W ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b LIFECELL CORPORATION   (United States)

Author keywords

Angiotensin II; Fibrosis; Renin; TGF

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; COLLAGEN TYPE 1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FIBRONECTIN; LOSARTAN; MATRIX PROTEIN; NEUTRALIZING ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT PROTEIN; RECOMBINANT RENIN; REMIKIREN; RENIN; RENIN INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL LYSATE; CONTROLLED STUDY; FETUS; HUMAN; HUMAN CELL; KIDNEY FIBROSIS; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN TARGETING; RAT; RNA ANALYSIS; RNA CONFORMATION; SUPERNATANT;

ANGIOTENSIN II; ANIMALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR MATRIX PROTEINS; FIBRONECTINS; GLOMERULAR MESANGIUM; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; RENIN; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 30944469631     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000011     Document Type: Article

References (46)

1. Griendling KK, Murphy TJ, Alexander RW. Molecular biology of the renin-angiotensin system. Circulation 1993; 87: 1816-1828.
2. van Kesteren CA, Danser AH, Derkx FH et al. Mannose 6-phosphate receptor-mediated internalization and activation of prorenin by cardiac cells. Hypertension 1997; 30: 1389-1396.
3. Admiraal PJ, van Kesteren CA, Danser AH et al. Uptake and proteolytic activation of prorenin by cultured human endothelial cells. J Hypertens 1999; 17: 621-629.
4. Sealey JE, Catanzaro DF, Lavin TN et al. Specific prorenin/renin binding (ProBP) - identification and characterization of a novel membrane site. Am J Hypertens 1996; 9: 491-502.
5. Nguyen G, Delarue F, Berrou J et al. Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int 1996; 50: 1897-1903.
6. Nguyen G, Delarue F, Burckle C et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109: 1417-1427.
7. Ichihara A, Hayashi M, Kaneshiro Y et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the 'handle' region for nonproteolytic activation of prorenin. J Clin Invest 2004; 114: 1128-1135.
8. Niimura F, Labosky PA, Kakuchi J et al. Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation. J Clin Invest 1995; 96: 2947-2954.
9. Tsuchida S, Matsusaka T, Chen X et al. Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes. J Clin Invest 1998; 101: 755-760.
10. Esther Jr CR, Howard TE, Marino EM et al. Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab Invest 1996; 74: 953-965.
11. Ray PE, McCune B, Gomez RA et al. Expression of transforming growth factor b3 in hypertrophic juxtaglomerular apparatus. N Engl J Med 1994; 330: 68-69.
12. Ray PE, McCune BK, Gomez RA et al. Renal vascular induction of TGF-β2 and renin by potassium depletion. Kidney Int 1993; 44: 1006-1013.
13. Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 1998; 31: 181-188.
14. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292.
15. Noble NA, Border WA. Angiotensin II in renal fibrosis: should TGF-β rather than blood pressure be the therapeutic target? Semin Nephrol 1997; 17: 455-466.
16. Tomooka S, Border WA, Marshall BC, Noble NA. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int 1992; 42: 1462-1469.
17. Vidotti DB, Casarini DE, Cristovam PC et al. High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am J Physiol Renal Physiol 2004; 286: F1039-F1045.
18. Andrade AQ, Casarini DE, Schor N, Boim MA. Characterization of renin mRNA expression and enzyme activity in rat and mouse mesangial cells. Braz J Med Biol Res 2002; 35: 17-24.
19. Seikaly MG, Arant Jr BS, Seney Jr FD. Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J Clin Invest 1990; 86: 1352-1357.
20. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431-2437.
21. Ganten D, Wagner J, Zeh K et al. Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc Natl Acad Sci USA 1992; 89: 7806-7810.
22. Bohlender J, Menard J, Wagner J et al. Human renin-dependent hypertension in rats transgenic for human angiotensinogen. Hypertension 1996; 27: 535-540.
23. Gaedeke J, Peters H, Noble NA, Border WA. Angiotensin II, TGF-β and renal fibrosis. Contrib Nephrol 2001; 135: 153-160.
24. Sharma K, Eltayeb BO, McGowan TA et al. Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 1999; 34: 818-823.
25. Laviades C, Varo N, Diez J. Transforming growth factor beta in hypertensives with cardiorenal damage. Hypertension 2000; 36: 517-522.
26. Peters H, Border WA, Noble NA. Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998; 54: 1570-1580.
27. Border WA, Noble NA. Maximizing hemodynamic-independent effects of angiotensin II antagonists in fibrotic diseases. Semin Nephrol 2001; 21: 563-572.
28. Kurtz A. Cellular control of renin secretion. Rev Physiol Biochem Pharmacol 1989; 113: 1-40.
29. Johns WD, Peach MJ, Gomez RA et al. Angiotensin II regulates renin gene expression. Am J Physiol 1990; 259: F882-F887.
30. Kurtz A, Wagner C. Regulation of renin secretion by angiotensin II-AT1 receptors. J Am Soc Nephrol 1999; 10(Suppl 11): S162-S168.
31. Azizi M, Bissery A, Lamarre-Cliche M, Menard J. Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans. Hypertension 2004; 43: 785-790.
32. Gomez RA, Chevalier RL, Everett AD et al. Recruitment of renin gene-expressing cells in adult rat kidneys. Am J Physiol 1990; 259: F660-F665.
33. Cheng HF, Wang SW, Zhang MZ et al. Prostaglandins that increase renin production in response to ACE inhibition are not derived from cyclooxygenase-1. Am J Physiol Regul Integr Comp Physiol 2002; 283: R638-R646.
34. Wagner C, Kurtz A. Effects of candesartan on the renin system in conscious rats. J Am Soc Nephrol 1999; 10(Suppl 11): S169-S171.
35. Kramer BK, Ritthaler T, Schweda F et al. Effects of the angiotensin II type-1 receptor antagonist ZD7155 on angiotensin II-mediated regulation of renin secretion and renal renin gene expression, renal vasoconstriction, and blood pressure in rats. J Cardiovasc Pharmacol 1998; 31: 700-705.
36. Yu L, Border WA, Anderson I et al. Combining TGF-β inhibition and angiotensin II blockade results in enhanced anti-fibrotic effect. Kidney Int 2004; 66: 1774-1784.
37. McQuillan DJ, Seo NS, Hocking AM, McQuillan CI. Recombinant expression of proteoglycans in mammalian cells. Utility and advantages of the vaccinia virus/T7 bacteriophage hybrid expression system. Methods Mol Biol 2001; 171: 201-219.
38. Hocking AM, Strugnell RA, Ramamurthy P, McQuillan DJ. Eukaryotic expression of recombinant biglycan: posttranslational processing and the importance of secondary structure for biological activity. J Biol Chem 1996; 271(32): 19571-19577.
39. Katz SA, Opsahl JA, Lunzer MM et al. Effect of bilateral nephrectomy on active renin, angiotensinogen, and renin glycoforms in plasma and myocardium. Hypertension 1997; 30: 259-266.
40. Okuda S, Languino LR, Ruoslahti E, Border WA. Elevated expression of transforming growth factor-β and proteoglycan production in experimental glomerulonephritis. J Clin Invest 1990; 86: 453-462.
41. Rennard SI, Berg R, Martin GR et al. Enzyme-linked immunoassay (ELISA) for connective tissue components. Anal Biochem 1980; 104: 205-214.
42. Yu L, Border WA, Huang Y, Noble NA. TGF-beta isoforms in renal fibrogenesis. Kidney Int 2003; 64: 844-856.
43. Kobori H, Harrison-Bernard LM, Navar LG. Expression of angiotensinogen mRNA and protein in angiotensin II-dependent hypertension. J Am Soc Nephrol 2001; 12: 431-439.
44. Jackson AL, Bartz SR, Schelter J et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003; 21: 635-637.
45. Bridge AJ, Pebernard S, Ducraux A et al. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 2003; 34: 263-264.
46. Hannon GJ. RNA interference. Nature 2002; 418: 244-251.